Evidence map›Paper›PMID 24677688›Full record

ArticlePharmacoepidemiology and drug safety2014

Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients.

Jenny I Shen, Maria E Montez-Rath, Aya A Mitani, Kevin F Erickson, Wolfgang C Winkelmayer

Open access · greenAbstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Does subjective assessment of dialyzer appearance reflect dialyzer performance in online hemodiafiltration?Hemodialysis international. International Symposium on Home Hemodialysis · 2020
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jenny I ShenDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Maria E Montez-Rath
Aya A Mitani
Kevin F Erickson
Wolfgang C Winkelmayer
Palo Alto University · USStanford Medicine · USStanford University · US

Funding

TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007357 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 1986 to 2022
$4.8M
Associations among RAAS Inhibitors, Residual Kidney Function, and CV Events in PDF32DK096765 · NIDDK · STANFORD UNIVERSITY · PI SHEN, JENNY I · 2012 to 2013
$121k
NIDDK NIH HHS F32 DK096765NIDDK NIH HHS F32DK096765NIDDK NIH HHS T32 DK007357
6 · The paper itself

Abstract

purposeHeparin is commonly used to anticoagulate the hemodialysis (HD) circuit. Despite the bleeding risk, no American standards exist for its administration. We identified correlates and quantified sources of variance in heparin dosing for HD.

methodsWe performed a cross-sectional study of patients aged 67 years or older who underwent HD with heparin on one of two randomly chosen days in 2008 at a national chain of dialysis facilities. Using a mixed effects model with random intercept for facility and fixed patient and facility characteristics, we examined heparin dosing at patient and facility levels.

resultsThe median heparin dose among the 17 722 patients treated in 1366 facilities was 4000 (25th-75th percentile: 2625-6000) units. In multivariable-adjusted analyses, higher weight, longer session duration, catheter use, and dialyzer reuse were significantly associated with higher heparin dose. Dose also varied considerably among census divisions. Of the overall variance in dose, 21% was due to between-facility differences, independent of facilities' case mix, geography, size, or rurality; 79% was due to differences at the patient level. The patient and facility characteristics in our model explained only 25% of the variance at the patient level.

conclusionsDespite the lack of standards for heparin administration, we noted patterns of use, including weight-based and time-dependent dosing. Most of the variance was at the patient level; however, only a quarter of it could be explained. The high amount of unexplained variance suggests that factors other than clinical need are driving heparin dosing and that there is likely room for more judicious dosing of heparin.

Indexed as

AgedAged, 80 and overAnticoagulantsCross-Sectional StudiesDose-Response Relationship, DrugFemaleHemorrhageHeparinHumansMaleRenal DialysisTime FactorsUnited StatesAnticoagulantsHeparinanticoagulationfacilityhemodialysisheparinpharmacoepidemiology

Identifiers

PMID24677688
PMCPMC4022350
OpenAlexW1539596880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.